Rapid Phenotypic AST Technologies: A Comprehensive Review of Commercial Systems for Clinical Microbiology
This review catalogs the current landscape of commercial rapid antimicrobial susceptibility testing systems that use novel methods to monitor bacterial growth and shorten turnaround time. The technologies covered include platforms designed for direct testing from clinical specimens, with the potential to expedite antimicrobial optimization. The review provides clinical microbiologists with a practical framework for evaluating emerging AST platforms.
The original study
Emerging technologies for rapid phenotypic antimicrobial susceptibility testing of clinical isolates of bacteria.
- Authors
- Rattin J, Boswell M, Rhoads D
- Journal
- Journal of clinical microbiology
- Type
- Journal Article, Review
- PMID
- 40899882
Original abstract
Providing timely and accurate antimicrobial susceptibility testing (AST) results is a crucial component of clinical microbiology practice. Commercial rapid AST (RAST) is an emerging and quickly expanding area. These phenotypic RAST systems use various novel methods to monitor bacterial growth and replication in order to shorten the duration of time required for testing. Implementation of RAST has the potential to expedite antimicrobial therapeutic optimization, which can improve patient care. This minireview describes the current state of commercial phenotypic RAST including tests designed to report antimicrobial susceptibilities directly from clinical specimens.